Archives of Pharmaceutical Sciences Ain Shams University (Jun 2019)

Apoptosis in cancer: from pathogenesis to discovery of advanced selective Bcl-2 family inhibitors

  • Samaa Abbas,
  • Nermin S. Abdou,
  • Deena S. Lasheen,
  • Dalal A. Abou El Ella

DOI
https://doi.org/10.21608/aps.2019.20225
Journal volume & issue
Vol. 3, no. 1
pp. 37 – 54

Abstract

Read online

Cancer is a genetic disease characterized by two features: unregulated cell growth and tissue invasion (metastasis). It can be viewed as the result of a succession of genetic changes during which a normal cell is transformed into a malignant one. Evasion of cell death, apoptosis, is one of the essential changes in a cell that cause this malignant transformation. Hence, reduced apoptosis or its resistance plays a vital role in carcinogenesis. The Bcl-2 family of proteins regulates the mitochondrial apoptotic pathway. Disease states arise upon deregulation of the Bcl-2 family of proteins, where cell death is either promoted or evaded; one of the most common tactic cancer cells utilize to promote survival is anti-apoptotic protein overexpression. Specifically, Bcl-2 overexpression has been shown to be a major chemoresistance factor in a number of human cancers, and for this reason, Bcl-2 targeting is a pharmacologic priority in the quest to reactivate cell death for therapeutic benefit in cancer.

Keywords